Enanta Pharmaceuticals Stock News

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immuno

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.

The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q4 2023 Earnings Conference Call November 20, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Execut

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for vira

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today anno

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $1.53 per share a year ago.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced

Shares of Enanta Pharmaceuticals Inc. ENTA, -0.25% gained 5% premarket on Tuesday after the biotech company released positive results from an early-phase clinical trial of a treatment for respiratory

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced t